NCT07465224PHASE2Recruiting
A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus
Alnylam Pharmaceuticals
Start Date
1/15/2026
Completion Date
5/28/2027
Summary
The purpose of this study is to evaluate the effect of a single dose of ALN-4324 on whole-body insulin sensitivity in participants with T2DM
Eligibility Criteria
Age Range: 18 years to 65 years
Inclusion Criteria:
* Is an adult patient with a confirmed diagnosis of T2DM
* Has a body mass index (BMI) of ≥23 kg/m\^2 to ≤39.9 kg/m\^2
* Has a hemoglobin A1c (HbA1c) ≥6.5% to \<10.5%
* Is on a stable dose of metformin, sodium-glucose cotransporter 2 inhibitor (SGLT2i), or dipeptidyl peptidase-4 inhibitor (DPP4i)
Exclusion Criteria:
* Has any clinically significant concomitant disease, medical condition, or abnormal laboratory finding that could compromise participant safety or confound interpretation of study results
* Receiving therapies known to interfere with glucose or insulin metabolism other than current treatment for T2DM or birth control methods
Note: other protocol defined inclusion/exclusion criteria apply
Interventions
DRUG
ALN-4324
DRUG
Placebo
Conditions
Type 2 Diabetes Mellitus (T2DM)
Locations
Clinical Trial Site
Chula Vista, California 91911
United States